Abstract:Abstract Rationale: As the result of genetic alterations and tumor hypoxia, cancer cells re-program metabolism to meet increased energy demand for enhanced anabolism, cell proliferation, and protection from oxidative damage and cell death signals. Whereas glycolysis and its regulation by the MYC oncogene product (Myc) have been intensively studied, glutaminolysis and anapleurosis, especially under hypoxia, have not been defined. Objectives: We sought to determine whether glutamine, a key source of nitrogen and anabolic carbon skeleton for mammalian cells, is still utilized under hypoxic condition and how it is regulated by MYC. Methods: We used NMR and FT-ICR-MS to resolve 13C and 15N labeling patterns of metabolites derived from labeled glutamine or glucose in the P493 human B lymphoma model that bear a tetracycline-repressible MYC, under normoxic and hypoxic conditions. Levels of specific enzymes, which are involved in glucose and glutamine metabolism, were determined by immunoblotting and LC-MRM-MS and compared with the metabolomic profiles. Measurements and Main Results: Myc regulates almost the entire glycolytic pathway. As expected for hypoxia, many glycolytic enzymes levels and lactate production were elevated, and 13C- glucose catabolism by the TCA cycle was significantly diminished. Myc elevated glutaminase (GLS, which converts glutamine to glutamate and NH4+), the glutamine transporter SLC1A5, and the transaminases GOT1 and GPT2, suggesting that transamination is favored with Myc activation. While GLS-mediated NH4+ release persisted under hypoxia, the Myc-induced transaminases favor the production of α-ketoglutarate without additional NH4+ production. The 13C labeling pattern of Ala is consistent with active mitochondrial GPT2 that transaminates 13C-pyruvate derived from 13C- glucose. Given that mitochondrial function is generally believed to be diminished by hypoxia, glutamine metabolism unexpectedly persisted in hypoxia with continued oxidation of glutamine carbons by the TCA cycle. The key enzymes and main products of 13C labeled glutamine were not decreased by hypoxia, and glutamine contributed to substantial de novo glutathione production in hypoxia. Because glutamine metabolism is sustained in hypoxia, which is pervasive in the tumor microenvironment, we sought to target glutaminase in vivo. We found that small molecule inhibition of glutaminase could diminish lymphoma and pancreatic cancer xenograft growth in vivo. Conclusions: Our studies reveal a previously unsuspected sustained glutamine metabolism in hypoxia. Glutamine contributes to TCA cycle carbons as well as enhances glutathione synthesis in hypoxia, suggesting that cancer cells reprogram metabolism via both glucose and glutamine to adapt to the tumor microenvironment. Our findings indicate that key nodal points in glutamine metabolism in addition to those in glycolysis could be targeted for therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2799. doi:10.1158/1538-7445.AM2011-2799

C-Myc Suppression of Mir-23A/b Enhances Mitochondrial Glutaminase Expression and Glutamine Metabolism.

Reprogramming Of Proline And Glutamine Metabolism Contributes To The Proliferative And Metabolic Responses Regulated By Oncogenic Transcription Factor C-Myc

Oncogenic Myc Induces Expression of Glutamine Synthetase through Promoter Demethylation.

C-Myc-induced Chemosensitization is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-Kappa B Activity in Pancreatic Cancer Cells.

Myc Promotes Glutaminolysis in Human Neuroblastoma Through Direct Activation of Glutaminase 2

MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities

N-Myc Promotes Glutamine Anaplerosis And Aggressive Tumor Progression Through Direct Gls2 Activation

MYC sensitises cells to apoptosis by driving energetic demand

miR‐145 inhibits aerobic glycolysis and cell proliferation of cervical cancer by acting on MYC

C-Myc Negatively Controls the Tumor Suppressor PTEN by Upregulating Mir-26A in Glioblastoma Multiforme Cells

C-Myc Modulates Glucose Metabolism Via Regulation of Mir-184/Pkm2 Pathway in Clear-Cell Renal Cell Carcinoma.

Mir-145 Inhibits Glutamine Metabolism Through C-Myc/gls1 Pathways in Ovarian Cancer Cells

Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by C-Myc*

Abstract 2799: Unexpected Sustained Hypoxic Glutamine Metabolism and Therapeutic Opportunities

Mitochondrial Mir-181A-5p Promotes Glucose Metabolism Reprogramming in Liver Cancer by Regulating the Electron Transport Chain.

Crosstalk of mTOR/PKM2 and STAT3/c-Myc signaling pathways regulate the energy metabolism and acidic microenvironment of gastric cancer.

Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis.

Data from MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor–Initiating Cells

C‐myc–impdh1/2 Axis Promotes Tumourigenesis by Regulating GTP Metabolic Reprogramming

C-Myc Overexpression Promotes Oral Cancer Cell Proliferation and Migration by Enhancing Glutaminase and Glutamine Synthetase Activity.

Cmyc-Mediated Activation of Serine Biosynthesis Pathway is Critical for Cancer Progression under Nutrient Deprivation Conditions